Lonza Expands Dual-Payload ADC Technology Offering Through Exclusive Access to Qurient’s CDK7 Inhibitors
- Lonza licenses Qurient CDK7 inhibitors for ADCs
- SYN-duo CC pairs exatecan with a CDK7 inhibitor
- Deal strengthens Lonza’s ADC technology offering
|
Lonza Group AG / Key word(s): Agreement
|
Basel, Switzerland and Seongnam, Korea, 12 October 2026 – Lonza, the world's leading contract development and manufacturing organization (CDMO), and Qurient Co. Ltd., a clinical-stage biopharmaceutical company, announced today an exclusive license agreement for the use of Qurient’s cyclin-dependent kinase 7 (CDK7) inhibitors for dual-payload antibody-drug conjugate (ADC) applications.
Dual-payload ADCs carry two different cytotoxic payloads on a single antibody, allowing them to attack each tumor cell through multiple mechanisms at the same time. The agreement includes Qurient’s highly selective and potent clinical stage CDK7 inhibitor designed to target multiple hallmarks of cancer.
Christian Seufert, Head of Advanced Synthesis, Lonza, commented: “Dual-payload ADCs are among the most promising areas of innovation for customers developing differentiated cancer therapies. This agreement adds a differentiated CDK7 inhibitor payload technology to Lonza’s ADC toolbox and further strengthens our ability to support customers from early technology evaluation through development, manufacturing and commercialization. With SYN-duo CC and customizable dual-payload formats, we can offer customers more choice and flexibility as they design and advance the next-generation of ADC programs.”

